Belatacept for kidney transplant recipients

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2014, Pages

  Masson, Philip ^a   Henderson, Lorna ^b   Chapman, Jeremy R ^c   Craig, Jonathan C ^a,d   Webster, Angela C ^a,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; GLUCOSE; LIPID; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; ABATACEPT; ANTIBODY CONJUGATE; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; BLOOD PRESSURE MEASUREMENT; CADAVER DONOR; DIABETES MELLITUS; DIALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; EPSTEIN BARR VIRUS; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIVING DONOR; POSTOPERATIVE INFECTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCAR FORMATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; GRAFT REJECTION; GRAFT SURVIVAL; LYMPHOPROLIFERATIVE DISORDERS; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; CALCINEURIN INHIBITORS; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MYCOPHENOLIC ACID; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; SIROLIMUS; TACROLIMUS;

EID: 84922223029     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010699.pub2     Document Type: Review

References (268)

1. Bremer S, Vethe NT, Rootwelt H, Jorgensen PF, Stenstrom J, Holdaas H, et al. Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. Journal of Translational Medicine 2009;7:64. [MEDLINE: 19635156]
2. Charpentier B, Grinyo J, Medina-Pestana J, Vanrenterghem I, Vincente F, Dong Y, et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no: O-242]. Transplant International 2011;24(Suppl 2):68-9. [EMBASE: 70527318]
3. Charpentier B, Medina Pestana JO, Del CR, Rostaing L, Grinyo J, Vanrenterghem Y, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. American Journal of Transplantation 2013;13(11):2884-91. [MEDLINE: 24103072]
4. Charpentier B, Vincenti F, Rice K, Campistol J, Duan T, Pupim L, et al. Three-year outcomes in patients with delayed graft function in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT) [abstract no: PO27.076]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012. [EMBASE: 71251772]
5. Dobbels F, Wong S, Joo S, Kalsekar A. Health-related quality of life after kidney transplantation: results from belatacept clinical trials [abstract no: 1099]. American Journal of Transplantation 2011;11(Suppl 2):352-3. [EMBASE: 70406145]
6. Dobbels F, Wong S, Min Y, Sam J, Kalsekar A. Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials. Transplantation 2014;98(9):960-8. [MEDLINE: 24831918]
7. Durrbach A, Citterio F, Mulloy L, David-Neto E, Russ G, Vitko S, et al. Renal function in patients treated with belatacept- or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT studies [abstract no: 230]. American Journal of Transplantation 2011;11(Suppl 2):100. [EMBASE: 70405265]
8. Durrbach A, Citterio F, Mulloy L, David-Neto E, Russ G, Vitko S, et al. Renal function in patients treated with belatacept- or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT studies [abstract no: Sa521]. NDT Plus 2011;4(Suppl 2):4.s2.60.
9. Durrbach A, Citterio F, Mulloy L, David-Neto E, Russ G, Vitko S, et al. Renal function in patients treated with belatacept-or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT studies [abstract no: P-080]. Transplant International 2011;24(Suppl 2):249. [EMBASE: 70527977]
10. Durrbach A, Florman S, Larsen C, Pestana JM, Vanrenterghem Y, Vincente F, et al. Primary outcomes from a randomized, phase III study of belatacept versus cyclosporine in ECD kidney transplants (BENEFIT-EXT study) [abstract no: 28]. American Journal of Transplantation 2010;10(Suppl 2):7. [EMBASE: 70081054]
11. Durrbach A, Florman S, Zhang R, Becker T, Grinyo J, Lang P, et al. Four-year outcomes by donor type from the long-term extension of the belatacept BENEFIT and BENEFIT-EXT Studies [abstract no: 1293]. American Journal of Transplantation 2012;12(Suppl 3):407. [EMBASE: 70747260]
12. Durrbach A, Florman S, Zhang R, Lang P, Lehner F, Massari P, et al. Five-year outcomes by donor type from the long-term extension of the belatacept BENEFIT-EXT Study [abstract no: B933]. American Journal of Transplantation 2013;13(Suppl S5):311. [EMBASE: 71057509]
13. Durrbach A, Grinyo J, Vanrenterghem Y, Becker T, Florman S, Lang P, et al. Belatacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial [abstract no: F568]. NDT Plus 2011;4(Suppl 2):4.s2.43.
14. Durrbach A, Larsen C, Medina PJ, Vanrenterghem Y, Vincenti F, Florman S, et al. Belatacept vs cyclosporine in ECD kidney transplants: two year outcomes from the BENEFIT-EXT study [abstract]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9-11; Bournemouth, UK. 2011.
15. Durrbach A, Larsen C, Medina-Pestana J, De Jonge H, Vincenti F, Florman S, et al. Belatacept vs cyclosporine in ECD kidney transplants: Two-year outcomes from the BENEFIT-EXT study [abstract no: 1394]. Transplantation 2010;90(Suppl):157. [EMBASE: 71531405]
16. Durrbach A, Larsen C, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Florman S, et al. Belatacept vs cyclosporine in ECD kidney transplant: two-year outcomes from the BENEFIT-EXT study [abstract no: 0089]. Transplant International 2010;23(Suppl 2):17.
17. Durrbach A, Larsen C, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Florman S, et al. Belatacept vs cyclosporine in ECD kidney transplants: two-year outcomes from the BENEFIT-EXT Study [abstract no: SA-FC444]. Journal of the American Society of Nephrology 2010;21(Abstracts):101A-2A.
18. Durrbach A, Larsen C, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Florman S, et al. Primary outcomes from a randomised, phase III study of belatacept vs cyclosporine in ECD kidney transplants (BENEFIT-EXE study) [abstract no: O49]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17-19; London, UK. 2010.
19. Durrbach A, Larsen C, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Florman S, et al. Primary outcomes from a randomized, phase 3 study of belatacept vs cyclosporine in ECD kidney transplants (BENEFIT-EXT study) [abstract no: SA-FC352]. Journal of the American Society of Nephrology 2009;20:82A-3A.
20. Durrbach A, Larsen C, Medina-Pestana JD, Vanrenterghem Y, Vincenti F, Florman S, et al. Primary outcomes from a randomized, phase III study of belatacept vs cyclosporine in ECD kidney transplants (BENEFIT-EXT Study) [abstract no: O-332]. Transplant International 2009;22(Suppl 2):89.
21. Durrbach A, Larsen C, Medina-Pestana JD, Vanrenterghem Y, Vincenti F, Florman S, et al. Primary outcomes from a randomized, phase III study of belatacept vs cyclosporine in ECD kidney transplants (BENEFIT-EXT study) [abstract no: 27]. American Journal of Transplantation 2009;9(Suppl 2):199.
22. Durrbach A, Larsen CP, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Florman S, et al. Belatacept vs cyclosporine in ECD kidney transplants: two-year outcomes from the BENEFIT-EXT study [abstract no: 143]. American Journal of Transplantation 2010;10(Suppl 4):83. [EMBASE: 70463504]
23. Durrbach A, Larsen CP, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Florman S, et al. Belatacept vs cyclsoporine in ECD kidney transplants: two-year outcomes from the BENEFIT-EXT study [abstract no: Sa652]. NDT Plus 2010;3(Suppl 3):iii262. [EMBASE: 70484118]
24. Durrbach A, Medina-Pestana J, Becker T, Grinyo J, Lang P, Garcia VD, et al. Four-year outcomes by donor type from the long-term extension of the belatacept BENEFIT and BENEFIT-EXT Studies [abstract no: PO27.057]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
25. Durrbach A, Medina-Pestana J, Pearson T, Vincenti F, Garcia VD, Campistol J, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). American Journal of Transplantation 2010;10(3):547-57. [MEDLINE: 20415898]
26. Durrbach A, Medina-Pestana J, Rostaing L, Breshahan B, Helderman JH, Rice K, et al. Improving or maintaining renal function with belatacept: 5 year BENEFIT long-term extension results [abstract no: BO199]. Transplant International 2013;26(Suppl 2):92. [EMBASE: 71359311]
27. Durrbach A, Medina-Pestana J, Vanrenterghem Y, Rial M, Charpentier B, Matas A, et al. Improving or maintaining renal function over 5 years with belatacept in recipients of extended-criteria donor kidneys [abstract no: O067]. Transplant International 2013;26(Suppl 2):44. [EMBASE: 71359105]
28. Durrbach A, Muehlbacher F, Florman S, Medina PJ, Jones-Burton C, Charpentier B. Outcomes at 3-years in EBV+ recipients of UNOS criteria ECD kidneys from a randomized trial (BENEFIT-EXT) comparing belatacept vs cyclosporine [abstract]. Transplantation 2014;98(Suppl 1):456-7. [EMBASE: 71545057]
29. Durrbach A, Muehlbacher F, Florman S, Medina Pestana J, Jones-Burton C, Charpentier B. Outcomes at 3-Years in EBV+ recipients of UNOS criteria ECD kidneys from a randomized trial (BENEFIT-EXT) comparing belatacept vs cyclosporine [abstract no: A202]. American Journal of Transplantation 2014;14(Suppl 3):456.
30. Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Muehlbacher F, et al. Three year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT) [abstract no: P145]. Transplant International 2011;24(Suppl 3):51. [EMBASE: 70537445]
31. Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, DeCarvalho D, Muehlbacher F, et al. Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT & BENEFIT-EXT) [abstract no: 229]. American Journal of Transplantation 2011;11(Suppl 2):100. [EMBASE: 70405264]
32. Florman S, Bresnahan B, Chan L, Helderman H, Dong Y, Harler MB, et al. Three year outcomes in Black/African American kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no: 1091]. American Journal of Transplantation 2011;11(Suppl 2):350. [EMBASE: 70406137]
33. Florman S, Durrbach A, Grinyo J, Medina-PestanaJ, Del Carmen Rial M, Vitko S, et al. 4 year results from the long term extension of the belatacept BENEFIT-EXT study [abstract no: 187]. American Journal of Transplantation 2012;12(Suppl 3):82. [EMBASE: 70746134]
34. Florman S, Durrbach A, Larsen C, Medina-Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase III study of belatacept vs cyclosporine in kidney transplantation (BENEFIT-EXT) [abstract no: 373]. American Journal of Transplantation 2010;10(Suppl 4):150.
35. Florman S, Durrbach A, Larsen C, Medina-Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT-EXT) [abstract no: 1773]. Transplantation 2010;90(Suppl):342. [EMBASE: 71531743]
36. Florman S, Durrbach A, Larsen C, Medina-Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor type from a phase III study of belatacept vs cyclosporine in kidney transplantation (BENEFIT-EXT) [abstract no: F-PO1997]. Journal of the American Society of Nephrology 2010;21(Abstracts):568A.
37. Florman S, Pestana J, Rial M, Rostaing L, Grinyo J, van Renterghem Y, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys [abstract no: B934]. American Journal of Transplantation 2013;13(Suppl S5):311. [EMBASE: 71057510]
38. Florman S, Rice K, Chan L, Steinberg S, Pearson T, Duan T, et al. Four year outcomes in Black/African American kidney transplant recipients from the long term-extension of the belatacept BENEFIT and BENEFIT-EXT studies [abstract no: 1284]. American Journal of Transplantation 2012;12(Suppl 3):404. [EMBASE: 70747251]
39. Florman S, Rice K, Chan L, Zhang R, Abouljoud M, Steinberg S, et al. Outcomes at five years in Black/African-American kidney transplant recipients from the long-term extension of the belatacept BENEFIT and BENEFIT-EXT studies [abstract no: B935]. American Journal of Transplantation 2013;13(Suppl S5):311. [EMBASE: 71057510]
40. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010;90(12):1521-7. [MEDLINE: 21088650]
41. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies [abstract no: 1417]. Transplantation 2010;90(Suppl):156. [EMBASE: 71531402]
42. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies [abstract no: 144]. American Journal of Transplantation 2010;10(Suppl 4):83. [EMBASE: 70463505]
43. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies [abstract no: SA-FC442]. Journal of the American Society of Nephrology 2010;21(Abstracts):101A.
44. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies [abstract no: Sa676]. NDT Plus 2010;3(Suppl 3):iii270. [EMBASE: 70484142]
45. Grinyo J, Charpentier B, Zhang R, Abouljoud M, Lehner F, Rial M, et al. Likelihood of improving or sustaining renal function over four years with belatacept or CSA: insights from the BENEFIT-EXT long-term extension study [abstract no: SA-OR115]. Journal of the American Society of Nephrology 2012;23:92A.
46. Grinyo J, Durrbach A, Rostaing L, Bresnahan B, Helderman J, Rice K, et al. Likelihood of improving or maintaining renal function over five years with belatacept or CsA: insights from the BENEFIT long-term extension study [abstract no: 492]. American Journal of Transplantation 2013;13(Suppl S5):182. [EMBASE: 71057069]
47. Grinyo J, Florman S, Medina-Pestana J, Del Carmen Rial M, Muehlbacher F, Durrbach A, et al. Long-term extension of the belatacept BENEFIT-EXT Study: Results at month 48 [abstract no: PO27.033]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
48. Grinyo J, Larsen C, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, et al. One year safety profile of belatacept in kidney transplant patients (BENEFIT & BENEFIT-EXT) [abstract no:TH-PO1016]. Journal of the American Society of Nephrology 2009;20:343A.
49. Grinyo J, Medina-Pestana J, Becker T, Rial M, Dong Y, Block A, et al. Likelihood of improving or sustaining renal function over three years with belatacept or CsA: Insights from the BENEFIT-EXT study [abstract no: 188]. American Journal of Transplantation 2012;12(Suppl 3):82. [EMBASE: 70746135]
50. Grinyo J, Rial M, Alberu J, Steinberg S, Manfro R, Nainan G, et al. Outcomes of switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: 3 year results from the long-term extension of a phase II study [abstract no: 491]. American Journal of Transplantation 2013;13(Suppl S5):182. [EMBASE: 71057068]
51. Grinyo J, Vanrenterghem Y, Durrbach A, Rial M, Charpentier B, Matas A, et al. Likelihood of improving or maintaining renal function in recipients of extended-criteria donor kidneys over five years with belatacept or CsA (BENEFIT-EXT long-term extension study) [abstract no: B931]. American Journal of Transplantation 2013;13(Suppl S5):310. [EMBASE: 71057507]
52. Larsen C, Alberu J, Massari P, Acevedo R, Kamar N, Lin C, et al. 4 year results from the long term extension of the belatacept BENEFIT study [abstract no: 186]. American Journal of Transplantation 2012;12(Suppl 3):82. [EMBASE: 70746133]
53. Larsen C, Bray R, Gebel H, Ganguly B, Kulbokas E, Brickman D, et al. Evaluation of donor specific antibodies in kidney transplant patients treated with belatacept- or cyclosporine-based immunosuppression in BENEFIT and BENEFIT-EXT [abstract no: O-244]. Transplant International 2011;24(Suppl 2):69. [EMBASE: 70527320]
54. Larsen C, Charpentier B, Grinyo JM, Medina-Pestana JD, Vanrenterghem Y, Vincenti F, et al. One year safety profile of belatacept in kidney transplant patients from the BENEFIT and BENEFIT-EXT Studies [abstract no: 1080]. American Journal of Transplantation 2009;9(Suppl 2):495.
55. Larsen C, Charpentier B, Grinyo JM, Medina-Pestana JD, Vanrenterghem Y, Vincenti F, et al. One year safety profile of belatacept in kidney transplant patients from the BENEFIT and BENEFIT-EXT studies [abstract no: O-335]. Transplant International 2009;22(Suppl 2):90.
56. Larsen C, Grinyo J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Dong Y, et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no: 228]. American Journal of Transplantation 2011;11(Suppl 2):99-100. [EMBASE: 70405263]
57. Larsen C, Vincenti F, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Long term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension (LTE) of the belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial (BENEFIT) study [abstract no: B937]. American Journal of Transplantation 2013;13(Suppl S5):312. [EMBASE: 71057513]
58. Larsen C, Vincenti F, Grinyo JM, Charpentier B, Di Russo GB, Garg P. Limited impact of acute rejection on graft outcomes in belatacept-treated kidney transplant recipients (BENEFIT/BENEFIT-EXT) [abstract no: P-397]. Transplant International 2009;22(Suppl 2):193.
59. Larsen CP, Grinyo J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90(12):1528-35. [MEDLINE: 21076381]
60. Lehner F, Budde K, Morales JM, Blancho G, Muehlbacher F, Rice K, et al. Impact of donor age on 3-year outcomes of extended criteria donor kidney recipients in BENEFIT-EXT [abstract no: BO197]. Transplant International 2013;26(Suppl 2):92. [EMBASE: 71359309]
61. Levy A, Johnston K, Kalsekar A, Schnitzler M, L'Italien G, Kasiske B. Modeled long term projections of clinical outcomes from BENEFIT and BENEFIT-EXT [abstract no: 1292]. American Journal of Transplantation 2012;12(Suppl S3):406-7. [EMBASE: 70747259]
62. Medina Pestana J, Grinyo J, Vanrenterghem Y, Becker T, Florman S, Lang P, et al. Belatacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3 year outcomes from the phase III BENEFIT-EXT trial [abstract no: O-241]. Transplant International 2011;24(Suppl 2):68. [EMBASE: 70527317]
63. Medina Pestana J, Grinyo J, Vanrenterghem Y, Becker T, Florman S, Lang P, et al. Belatacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial [abstract no: 1088]. American Journal of Transplantation 2011;11(Suppl 2):349. [EMBASE: 70406134]
64. Medina Pestana J, Grinyo J, Vanrenterghem Y, Becker T, Florman S, Lang P, et al. Belatacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial [abstract no: P143]. Transplant International 2011;24(Suppl 3):51. [EMBASE: 70537443]
65. Medina-Pestana J, Campistol J, Del Carmen Rial M, Duro G, Becker T, Agarwal M, et al. Belatacept preserves renal function and structure at 1 year compared with cyclosporine in extended criteria donor (ECD) kidney transplant patients (BENEFIT-EXE) [abstract no: O53]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17-19; London, UK. 2010.
66. Medina-Pestana J, Grinyo J, Vanrenterghem I, Becker T, Florman S, Lang P, et al. Belatacept compared with ciclosporin in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial [abstract]. British Transplantation Society (BTS). 15th Annual Congress; 2012 Feb 22-24; Glasgow, UK. 2012.
67. Medina-Pestana JD, Campistol JM, Del Carmen Rial M, Garcia VD, Becker T, Agarwal M, et al. Belatacept is associated with preservation of renal function and structure at 1 year compared to cyclosporine in extended criteria donor (ECD) kidney transplant patients (BENEFIT-EXT Study) [abstract no: O-333]. Transplant International 2009;22(Suppl 2):89.
68. Medina-Pestana JD, Campistol JM, del C Rial M, Garcia VD, Becker T, Agarwal M, et al. Belatacept is associated with preservation of renal function and structure at 1 year compared to cyclosporine in extended criteria donor (ECD) kidney transplant patients (BENEFIT-EXT study) [abstract no: 28]. American Journal of Transplantation 2009;9(Suppl 2):199.
69. Medina-Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. American Journal of Transplantation 2012;12(3):630-9. [MEDLINE: 22300431]
70. Muehlbacher F, Becker T, Campistol J, Carvalho D, Florman S, Lang P, et al. Donor sub-type analysis of three year outcomes from a phase III study of belatacept in recipients of extended criteria donor kidneys (BENEFIT-EXT Trial) [abstract no: RO-331]. Transplant International 2011;24(Suppl 2):221-2. [EMBASE: 70527872]
71. Muehlbacher F, Durrbach A, Florman S, Medina PJ, Harler M, Larsen C. Outcomes at 3-years in EBV+ recipients of deceased donor kidneys from two randomized trials (BENEFIT and BENEFIT-EXT) comparing belatacept vs cyclosporine [abstract]. Transplantation 2014;98(Suppl 1):455. [EMBASE: 71545051]
72. Muehlbacher F, Florman S, Medina-Pestana J, Rial M, Rostaing L, Grinyo J, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys [abstract no: O066]. Transplant International 2013;26(Suppl 2):44. [EMBASE: 71359104]
73. Muehlbacher F, Florman S, Zhang R, Lang P, Lehner F, Massari P, et al. 5-year outcomes by donor type from the long-term extension of the belatacept BENEFIT-EXT study [abstract no: BO198]. Transplant International 2013;26(Suppl 2):92.
74. Muelbacher F, Becker T, Campistol J, Carvalho D, Florman S, Lang P. Donor sub-type analysis of 3 year outcomes from a phase III study of belatacept in recipient of extended criteria donor kidneys (BENEFIT-EXT trial) [abstract]. British Transplantation Society (BTS). 15th Annual Congress; 2012 Feb 22-24; Glasgow, UK. 2012.
75. Rice K, Chan L, Rostaing L, Bresnahan B, Helderman JH, Harler MB, et al. Likelihood of improving or sustaining renal function over four years with belatacept or CsA: insights from the BENEFIT Long-Term Extension Study [abstract no: TH-PO1042]. Journal of the American Society of Nephrology 2012;23:340A.
76. Rice K, Vanrenterghem Y, Merville P, Muehlbacher F, Zhang R, Duan T, et al. Three year outcomes in elderly kidney transplant recipients treated with belatacept vs cyclosporine in BENEFIT-EXT [abstract no: 1281]. American Journal of Transplantation 2012;12(Suppl 3):403. [EMBASE: 70747247]
77. Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, et al. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(11):2696-704. [MEDLINE: 21921152]
78. Rostaing L, Reyes-Acevedo R, Neumayer H, Vitko S, Xing J, Thomas D, et al. Outcomes at 3 years in kidney transplant recipients with pre-transplant diabetes from two phase 3 belatacept studies [abstract no: O-243]. Transplant International 2011;24(Suppl 2):69. [EMBASE: 70527319]
79. Rostaing L, Reyes-Acevedo R, Neumayer H, Vitko S, Xing J, Thomas D, et al. Outcomes at 3 years in kidney transplant recipients with pre-transplant diabetes from two phase III belatacept studies [abstract]. British Transplantation Society (BTS). 15th Annual Congress; 2012 Feb 22-24; Glasgow, UK. 2012.
80. Rostaing L, Vincenti F, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Long-term belatacept maintains efficacy & safety: 5-year BENEFIT long-term extension (LTE) results [abstract no: O065]. Transplant International 2013;26(Suppl 2):44. [EMBASE: 71359103]
81. Rostaing L, Vincenti F, Neumayer H, Reyes-Acevedo R, Block A, Di Russo G, et al. Belatacept demonstrates superior composite patient/graft survival in diabetic kidney transplant recipients vs. CsA: Results from BENEFIT & BENEFIT-EXT [abstract no: F-PO2028]. Journal of the American Society of Nephrology 2009;20:573a.
82. Rostaing L, Vincenti F, Neumayer H, Reyes-Acevedo R, Block A, Di Russo GB, et al. Belatacept demonstrates superior composite patient/graft survival in diabetic kidney transplant recipients vs CsA: results from the BENEFIT and BENEFIT-EXT studies [abstract no: 763]. American Journal of Transplantation 2009;9(Suppl 2):412.
83. Rostaing L, Vincenti F, Neumayer HH, Reyes-Acevedo R, Block AJ, Di Russo GB. Belatacept demonstrates superior composite patient/graft survival in diabetic kidney transplant recipients vs CSA: results from the BENEFIT and BENEFIT-EXT studies [abstract no: P-395]. Transplant International 2009;22(Suppl 2):192.
84. Russ G, Agarwal M, Becker T, Bresnahan B, Campistol JM, Darji P, et al. Belatacept associated with preserved renal function and structure compared with cyclosporine (CSA) in kidney transplant patients [abstract]. Immunology & Cell Biology 2010;88(6):A11-2. [EMBASE: 70313652]
85. Russ G, Durrbach A, Larsen CP, Medina-Pestana J, Vanrenterghem Y, et al. BENEFIT-EXT study two year outcomes: belatacept vs cyclosporine (CSA) in extended criteria donor (ECD) kidney transplants [abstract no: 2]. Transplantation Society of Australia & New Zealand (TSANZ). 29th Annual Scientific Meeting 2011 Jun 29-Jul 1, Canberra, Australia. 2011:37.
86. Shen J, Gelb JS, Townsend RM, Zhou Z, Pfister M, Harler MB, et al. Rationale for belatacept less intensive regimen in renal transplant recipients [abstract no: 1096]. American Journal of Transplantation 2011;11(Suppl 2):352. [EMBASE: 70406142]
87. Sherrill B, Wang J, Hall D, Kalsekar A. A Q-TWiST analysis of belatacept compared with cyclosporine in kidney transplant recipients [abstract no: SA-OR114]. Journal of the American Society of Nephrology 2012;23:92A.
88. Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyo J, Neumayer HH, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011;91(9):976-83. [MEDLINE: 21372756]
89. Vanrenterghem Y, Mancilla-Urrea E, Lang P, Agarwal M, Block A, Xing J. Belatacept is associated with improved cardiovascular and metabolic risk factors compared to cyclosporine in kidney transplant patients (BENEFIT & BENEFIT-EXE Studies) [abstract no: O52]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17-19; London, UK. 2010.
90. Vanrenterghem Y, Mancilla-Urrea E, Lang P, Agarwal M, Block A, Xing J. Belatacept is associated with improved cardiovascular and metabolic risk factors compared to cyclosporine in kidney transplant patients (BENEFIT & BENEFIT-EXT studies) [abstract no: TH-PO1018]. Journal of the American Society of Nephrology 2009;20:343a.
91. Vanrenterghem Y, Mancilla-Urrea E, Lang P, Agarwal M, Block AJ. Belatacept is associated with improved cardiovascular and metabolic risk factors compared to cyclosporine in kidney transplant patients (BENEFITand BENEFIT-EXT studies) [abstract no: O-334]. Transplant International 2009;22(Suppl 2):90.
92. Vanrenterghem Y, Mancilla-Urrea E, Lang P, Agarwal M, Block AJ, Xing J. Belatacept is associated with improved cardiovascular and metabolic risk factors compared to cyclosporine in kidney transplant patients (BENEFIT and BENEFIT-EXT Studies) [abstract no: 1079]. American Journal of Transplantation 2009;9(Suppl 2):495.
93. Vanrenterghem Y, Medina-Pestana J, Becker T, Rial M, Agarwal M, Lin CS, et al. Likelihood of improving or sustaining renal function over three years with belatacept or CsA: Insights from the BENEFIT-EXT Study [abstract no: PO27.056]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
94. Vincenti F, Grinyo J, Larsen C, Medina-Pestana J, Vanrenterghem Y, Dong Y, et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no: F564]. NDT Plus 2011;4(Suppl 2):4.s2.43.
95. Vincenti F, Grinyo J, Larsen C, Medina-Pestana J, Vanrenterghem Y, Duan T, et al. Benefit-risk profile of the belatacept LI regimen at 2 years in EBV(+) kidney transplant recipients [abstract no: 3370]. Transplantation 2010;90(Suppl):649. [EMBASE: 71532340]
96. Vincenti F, Rostaing L, Durrbach A, Rice K, Pupim L, Grinyo J. Improving or maintaining renal function over 5 years with belatacept or cyclosporine (CsA): insights from the BENEFIT and BENEFIT-EXT long-term extension (LTE) studies [abstract no: SA-PO1012]. Journal of the American Society of Nephrology 2013;24(Abstracts):860A.
97. Zhou Z, Shen J, Kaul S, Pfister M, Roy A. Belatacept population pharmacokinetics in renal transplant patients [abstract no: 1505]. American Journal of Transplantation 2010;10(Suppl 4):467.
98. Blancho G, Budde K, Merville P, Moal M, Rostaing L, Harler M, et al. Outcomes at 3 years in EBV+ European subpopulations from BENEFIT and BENEFIT-EXT [abstract no: A198]. American Journal of Transplantation 2014;14(Suppl 5):455. [EMBASE: 71545053]
99. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. American Journal of Transplantation 2008;8(10):2086-96. [MEDLINE: 18828769]
100. Bray R, Gebel H, Brannon P, Ganguly B, Townsend R, Meier-Kriesche U, et al. Evaluation of donor-specific antibodies through 5 years with belatacept in BENEFIT and BENEFIT-EXT [abstract no: 2163]. American Journal of Transplantation 2014;14(Suppl 3):117. [EMBASE: 71543898]
101. Bresnahan B, Vincenti F, Grinyo J, Charpentier B, Russo GD, Garg P, et al. Renal benefit of belatacept versus cyclosporine in kidney transplant patients is not impacted by acute rejection (BENEFIT study) [abstract no: 56]. American Journal of Transplantation 2010;10(Suppl 2):14. [EMBASE: 70081079]
102. Charpentier B, Grinyo J, Medina-Pestana J, Vanrenterghem I, Vincente F, Dong Y, et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no: O-242]. Transplant International 2011;24(Suppl 2):68-9. [EMBASE: 70527318]
103. Charpentier B, Vincenti F, Rice K, Campistol J, Duan T, Pupim L, et al. Three-year outcomes in patients with delayed graft function in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT) [abstract no: PO27.076]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
104. Dobbels F, Wong S, Joo S, Kalsekar A. Health-related quality of life after kidney transplantation: Results from belatacept clinical trials [abstract no: 1099]. American Journal of Transplantation 2011;11(Suppl 2):352-3. [EMBASE: 70406145]
105. Dobbels F, Wong S, Min Y, Sam J, Kalsekar A. Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials. Transplantation 2014;98(9):960-8. [MEDLINE: 24831918]
106. Dobbels F, Wong S, You M, Kalsekar A. Patient reports of immunosuppressant related side-effects after kidney transplantation: results from the belatacept phase III clinical trial (BENEFIT) [abstract no: 1100]. American Journal of Transplantation 2011;11(Suppl 2):353. [EMBASE: 70406146]
107. Durrbach A, Citterio F, Mulloy L, David-Neto E, Russ G, Vitko S, et al. Renal function in patients treated with belatacept- or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT studies [abstract no: 230]. American Journal of Transplantation 2011;11(Suppl 2):100. [EMBASE: 70405265]
108. Durrbach A, Citterio F, Mulloy L, David-Neto E, Russ G, Vitko S, et al. Renal function in patients treated with belatacept- or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT studies [abstract no: Sa521]. NDT Plus 2011;4(Suppl 2):4.s2.60.
109. Durrbach A, Citterio F, Mulloy L, David-Neto E, Russ G, Vitko S, et al. Renal function in patients treated with belatacept-or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT studies [abstract no: P-080]. Transplant International 2011;24(Suppl 2):249. [EMBASE: 70527977]
110. Durrbach A, Florman S, Zhang R, Becker T, Grinyo J, Lang P, et al. Four-year outcomes by donor type from the long-term extension of the belatacept BENEFIT and BENEFIT-EXT Studies [abstract no: 1293]. American Journal of Transplantation 2012;12(Suppl 3):407. [EMBASE: 70747260]
111. Durrbach A, Medina-Pestana J, Becker T, Grinyo J, Lang P, Garcia VD, et al. Four-year outcomes by donor type from the long-term extension of the belatacept BENEFIT and BENEFIT-EXT Studies [abstract no: PO27.057]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
112. Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Muehlbacher F, et al. Three year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT) [abstract no: P145]. Transplant International 2011;24(Suppl 3):51. [EMBASE: 70537445]
113. Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, DeCarvalho D, Muehlbacher F, et al. Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT & BENEFIT-EXT) [abstract no: 229]. American Journal of Transplantation 2011;11(Suppl 2):100. [EMBASE: 70405264]
114. Florman S, Bresnahan B, Chan L, Helderman H, Dong Y, Harler MB, et al. Three year outcomes in Black/African American kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no: 1091]. American Journal of Transplantation 2011;11(Suppl 2):350. [EMBASE: 70406137]
115. Florman S, Rice K, Chan L, Steinberg S, Pearson T, Duan T, et al. Four year outcomes in Black/African American kidney transplant recipients from the long term-extension of the belatacept BENEFIT and BENEFIT-EXT studies [abstract no: 1284]. American Journal of Transplantation 2012;12(Suppl 3):404. [EMBASE: 70747251]
116. Florman S, Rice K, Chan L, Zhang R, Abouljoud M, Steinberg S, et al. Outcomes at five years in Black/African-American kidney transplant recipients from the long-term extension of the belatacept BENEFIT and BENEFIT-EXT studies [abstract no: B935]. American Journal of Transplantation 2013;13(Suppl S5):311. [EMBASE: 71057510]
117. Furuzawa-Carballeda J, Lima G, Alberu J, Palafox D, Uribe-Uribe N, Morales-Buenrostro LE, et al. Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4alpha senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A. Clinical & Experimental Immunology 2012;167(2):330-7. [MEDLINE: 22236010]
118. Furuzawa-Carballeda J, Lima G, Uribe-Uribe N, Avila-Casado C, Mancilla E, Morales-Buenrostro LE, et al. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplantation Proceedings 2010;42(9):3489-96. [MEDLINE: 21094802]
119. Grimbert P, Audard V, Diet C, Matignon M, Plonquet A, Mansour H, et al. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. Nephrology Dialysis Transplantation 2011;26(3):1087-93. [MEDLINE: 20667993]
120. Grinyo J, Abouljoud M, Germain M, Manfro R, Morales J, Legendre C, et al. Likelihood of improving or sustaining renal function over 3 years with belatacept or ciclosporin: insights from the BENEFIT study [abstract]. British Transplantation Society (BTS). 15th Annual Congress; 2012 Feb 22-24; Glasgow, UK. 2012.
121. Grinyo J, Abouljoud M, Germain M, Manfro R, Morales J, Legendre C, et al. Likelihood of improving or sustaining renal function over three years with belatacept or CsA: insights from the BENEFIT study [abstract no: 1087]. American Journal of Transplantation 2011;11(Suppl 2):349. [EMBASE: 70406133]
122. Grinyo J, Abouljoud M, Germain MJ, Manfro R, Morales J, Legendre C, et al. Improving or sustaining renal function over 3 years with belatacept or cyclosporine A (CsA): insights from the BENEFIT study [abstract no: P-083]. Transplant International 2011;24(Suppl 2):250. [EMBASE: 70527980]
123. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010;90(12):1521-7. [MEDLINE: 21088650]
124. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies [abstract no: 144]. American Journal of Transplantation 2010;10(Suppl 4):83. [EMBASE: 70463505]
125. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies [abstract no: SA-FC442]. Journal of the American Society of Nephrology 2010;21(Abstracts):101A.
126. Grinyo J, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies [abstract no: Sa676]. NDT Plus 2010;3(Suppl 3):iii270. [EMBASE: 70484142]
127. Grinyo J, Charpentier B, Pestana JOM, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies [abstract no: 1417]. Transplantation 2010;90(Suppl):156. [EMBASE: 71531402]
128. Grinyo J, Larsen C, Charpentier B, Medina-Pestana J, Vanrenterghem Y, Vincenti F, et al. One year safety profile of belatacept in kidney transplant patients (BENEFIT & BENEFIT-EXT) [abstract no: TH-PO1016]. Journal of the American Society of Nephrology 2009;20:343A.
129. Grinyo J, Mondragon-Ramirez G, Darji P, Bresnahan B, Pearson T, Di Russo G, et al. Belatacept is associated with preservation or renal function and structure at 1 year compared to cyclosporine in kidney transplant patients (BENEFIT study) [abstract no: O51]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17-19; London, UK. 2010.
130. Grinyo J, Mondragon-Ramirez G, Darji P, Bresnahan B, Pearson T, DiRusso G, et al. Belatacept is associated with preservation of renal function and structure at 1 year vs cyclosporine in kidney transplant patients (BENEFIT Study) [abstract no: SA-FC358]. Journal of the American Society of Nephrology 2009;20:84a.
131. Grinyo JM, Mondragon-Ramirez G, Darji P, Bresnahan B, Pearson T, Di Russo GB, et al. Belatacept is associated with preservation of renal function and structure at 1 year compared to cyclosporine in kidney transplant patients (BENEFIT Study) [abstract no: 236]. American Journal of Transplantation 2009;9(Suppl 2):258-9. [EMBASE: 70010109]
132. Grinyo JM, Mondragon-Ramirez G, Darji P, Bresnahan B, Pearson T, Di Russo GB, et al. Belatacept is associated with preservation of renal function and structure at 1 year compared to cyclosporine in kidney transplant patients (BENEFIT Study) [abstract no: P-396]. Transplant International 2009;22(Suppl 2):193.
133. Kamar N, Ribes D, Lavit M, Esposito L, Lavayssiere L, Cointault O, et al. Pharmacokinetic monitoring of mycophenolate mofetil in de novo kidney transplant patients receiving belatacept or cyclosporine A [abstract no: 783]. American Journal of Transplantation 2007;7(Suppl 2):349.
134. Kamar N, Ribes D, Lavit M, Esposito L, Lavayssiere L, Cointault O, et al. Pharmacokinetic monitoring of mycophenolate mofetil in de novo kidney-transplant patients receiving belatacept or cyclosporine A [abstract no: P094]. Transplant International 2007;20(Suppl 2):118.
135. Larsen C, Bray R, Gebel H, Ganguly B, Kulbokas E, Brickman D, et al. Evaluation of donor specific antibodies in kidney transplant patients treated with belatacept- or cyclosporine-based immunosuppression in BENEFIT and BENEFIT-EXT [abstract no: O-244]. Transplant International 2011;24(Suppl 2):69. [EMBASE: 70527320]
136. Larsen C, Charpentier B, Grinyo JM, Medina-Pestana JD, Vanrenterghem Y, Vincenti F, et al. One year safety profile of belatacept in kidney transplant patients from the BENEFIT and BENEFIT-EXT Studies [abstract no: 1080]. American Journal of Transplantation 2009;9(Suppl 2):495.
137. Larsen C, Charpentier B, Grinyo JM, Medina-Pestana JD, Vanrenterghem Y, Vincenti F, et al. One year safety profile of belatacept in kidney transplant patients from the BENEFIT and BENEFIT-EXT studies [abstract no: O-335]. Transplant International 2009;22(Suppl 2):90.
138. Larsen C, Grinyo J, Charpentier B, Medina PJ, Kamar N, Vanrenterghem Y, et al. Belatacept vs cyclosporine in kidney transplant recipients: two year outcomes from the BENEFIT study [abstract no: 0076]. Transplant International 2010;23(Suppl 2):17.
139. Larsen C, Grinyo J, Charpentier B, Medina-Pestana J, Kamar N, Vanrenterghem Y, et al. Belatacept vs cyclosporine in kidney transplant recipients: Two year outcomes from the BENEFIT study [abstract]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9-11; Bournemouth, UK. 2011.
140. Larsen C, Grinyo J, Charpentier B, Medina-Pestana J, Kamar N, Vanrenterghem Y, et al. Belatacept vs cyclosporine in kidney transplant recipients: two-year outcomes from the BENEFIT Study [abstract no: SA-FC443]. Journal of the American Society of Nephrology 2010;21(Abstracts):101A.
141. Larsen C, Grinyo J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Dong Y, et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no: 228]. American Journal of Transplantation 2011;11(Suppl 2):99-100. [EMBASE: 70405263]
142. Larsen C, Grinyo JM, Charpentier B, Medina-Pestana J, Kamar N, Vanrenterghem Y, et al. Belatacept vs cyclosporine in kidney transplant recipients: two-year outcomes from the BENEFIT study [abstract no: 1374]. Transplantation 2010;90(Suppl):158.
143. Larsen C, Vincenti F, Grinyo JM, Charpentier B, Di Russo GB, Garg P. Limited impact of acute rejection on graft outcomes in belatacept-treated kidney transplant recipients (BENEFIT/BENEFIT-EXT) [abstract no: P-397]. Transplant International 2009;22(Suppl 2):193.
144. Larsen C, Vincenti F, Grinyo JM, Charpentier B, Di Russo GB, Garg P, et al. Renal benefit of belatacept vs cyclosporine in kidney transplant patients is not impacted by acute rejection (BENEFIT study) [abstract no: 100]. American Journal of Transplantation 2009;9(Suppl 2):220. [EMBASE: 70009973]
145. Larsen CP, Grinyo J, Charpentier B, Medina Pestana J, Kamar N, Vanrenterghem YF, et al. Belatacept vs cyclosporine in kidney transplant recipients: two-year outcomes from the BENEFIT Study [abstract no: 142]. American Journal of Transplantation 2010;10(Suppl 4):82. [EMBASE: 70463503]
146. Larsen CP, Grinyo J, Charpentier B, Pestana JM, Kamar N, Vanrenterghem Y, et al. Belatacept vs cyclosporine in kidney transplant recipients: two-year outcomes from the BENEFIT study [abstract no: Sa653]. NDT plus 2010;3(Suppl 3):iii262. [EMBASE: 70484119]
147. Larsen CP, Grinyo J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90(12):1528-35. [MEDLINE: 21076381]
148. Latek R, Fleener C, Lamian V, Kulbokas E, Davis PM, Suchard SJ, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009;87(6):926-33. [EMBASE: 19300198]
149. Levy A, Johnston K, Kalsekar A, Schnitzler M, L'Italien G, Kasiske B. Modeled long term projections of clinical outcomes from BENEFIT and BENEFIT-EXT [abstract no: 1292]. American Journal of Transplantation 2012;12(Suppl S3):406-7. [EMBASE: 70747259]
150. Muehlbacher F, Durrbach A, Florman S, Medina PJ, Harler M, Larsen C. Outcomes at 3-years in EBV+ recipients of deceased donor kidneys from two randomized trials (BENEFIT and BENEFIT-EXT) comparing belatacept vs cyclosporine [abstract]. Transplantation 2014;98(Suppl 1):455. [EMBASE: 71545051]
151. Muehlbacher F, Durrbach A, Florman S, Medina Pestana J, Harler M, Larsen C. Outcomes at 3-Years in EBV+ recipients of deceased donor kidneys from two randomized trials (BENEFIT and BENEFIT EXT) comparing belatacept vs cyclosporine [abstract no: A196]. American Journal of Transplantation 2014;14(Suppl 3):455.
152. Pearson T, Vincenti F, Grinyo J, Charpentier B, Medina-Pestana J, Rostaing L, et al. Primary outcomes from a randomized, phase III study of belatacept versus cyclosporine in kidney transplant recipients (BENEFIT study) [abstract no: 25]. American Journal of Transplantation 2010;10(Suppl 2):6. [EMBASE: 70081051]
153. Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, et al. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(11):2696-704. [MEDLINE: 21921152]
154. Rostaing L, Reyes-Acevedo R, Neumayer H, Vitko S, Xing J, Thomas D, et al. Outcomes at 3 years in kidney transplant recipients with pre-transplant diabetes from two phase 3 belatacept studies [abstract no: O-243]. Transplant International 2011;24(Suppl 2):69. [EMBASE: 70527319]
155. Rostaing L, Reyes-Acevedo R, Neumayer H, Vitko S, Xing J, Thomas D, et al. Outcomes at 3 years in kidney transplant recipients with pre-transplant diabetes from two phase III belatacept studies [abstract]. British Transplantation Society (BTS). 15th Annual Congress; 2012 Feb 22-24; Glasgow, UK. 2012.
156. Rostaing L, Vincenti F, Grinyo J, Rice KM, Bresnahan B, Steinberg S, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT Study. American Journal of Transplantation 2013;13(11):2875-83. [MEDLINE: 24047110]
157. Rostaing L, Vincenti F, Neumayer H, Reyes-Acevedo R, Block A, Di Russo G, et al. Belatacept demonstrates superior composite patient/graft survival in diabetic kidney transplant recipients vs. CsA: Results from BENEFIT & BENEFIT-EXT [abstract no: F-PO2028]. Journal of the American Society of Nephrology 2009;20:573A.
158. Rostaing L, Vincenti F, Neumayer H, Reyes-Acevedo R, Block A, Di Russo GB, et al. Belatacept demonstrates superior composite patient/graft survival in diabetic kidney transplant recipients vs CsA: results from the BENEFIT and BENEFIT-EXT studies [abstract no: 763]. American Journal of Transplantation 2009;9(Suppl 2):412.
159. Rostaing L, Vincenti F, Neumayer HH, Reyes-Acevedo R, Block AJ, Di Russo GB. Belatacept demonstrates superior composite patient/graft survival in diabetic kidney transplant recipients vs CSA: results from the BENEFIT and BENEFIT-EXT studies [abstract no: P-395]. Transplant International 2009;22(Suppl 2):192.
160. Russ G, Agarwal M, Becker T, Bresnahan B, Campistol JM, Darji P, et al. Belatacept associated with preserved renal function and structure compared with cyclosporine (CSA) in kidney transplant patients [abstract]. Immunology & Cell Biology 2010;88(6):A11-2. [EMBASE: 70313652]
161. Shen J, Gelb JS, Townsend RM, Zhou Z, Pfister M, Harler MB, et al. Rationale for belatacept less intensive regimen in renal transplant recipients [abstract no: 1096]. American Journal of Transplantation 2011;11(Suppl 2):352. [EMBASE: 70406142]
162. Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyo J, Neumayer HH, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011;91(9):976-83. [MEDLINE: 21372756]
163. Vanrenterghem Y, Mancilla-Urrea E, Lang P, Agarwal M, Block A, Xing J. Belatacept is associated with improved cardiovascular and metabolic risk factors compared to cyclosporine in kidney transplant patients (BENEFIT & BENEFIT-EXE Studies) [abstract no: O52]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17-19; London, UK. 2010.
164. Vanrenterghem Y, Mancilla-Urrea E, Lang P, Agarwal M, Block A, Xing J. Belatacept is associated with improved cardiovascular and metabolic risk factors compared to cyclosporine in kidney transplant patients (BENEFIT & BENEFIT-EXT studies) [abstract no: TH-PO1018]. Journal of the American Society of Nephrology 2009;20:343A.
165. Vanrenterghem Y, Mancilla-Urrea E, Lang P, Agarwal M, Block AJ. Belatacept is associated with improved cardiovascular and metabolic risk factors compared to cyclosporine in kidney transplant patients (BENEFITand BENEFIT-EXT studies) [abstract no: O-334]. Transplant International 2009;22(Suppl 2):90.
166. Vanrenterghem Y, Mancilla-Urrea E, Lang P, Agarwal M, Block AJ, Xing J. Belatacept is associated with improved cardiovascular and metabolic risk factors compared to cyclosporine in kidney transplant patients (BENEFIT and BENEFIT-EXT Studies) [abstract no: 1079]. American Journal of Transplantation 2009;9(Suppl 2):495.
167. Vincente F, Charpentier B, Rostaing L, Reyes-Acevedo R, Massari P, Vitko S, et al. Long-term extension of the belatacept BENEFIT Study: Results at month 48 [abstract no: MO05.01]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
168. Vincenti F, Charpentier B, Rostaing L, Reyes-Acevedo R, Massari P, Vitko S, et al. Long-term extension of the belatacept BENEFIT Study: results at month 48 [abstract no: PO27.001]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
169. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). American Journal of Transplantation 2010;10(3):535-46. [MEDLINE: 20415897]
170. Vincenti F, Grinyo J, Charpentier B, Medina PJ, Rostaing L, Vanrenterghem Y, et al. Primary outcomes from a randomised, phase III study of belatacept vs cyclosporine in kidney transplant recipients (BENEFIT study) [abstract no: O50]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17-19; London, UK. 2010.
171. Vincenti F, Grinyo J, Charpentier B, Pestana J, Rostaing L, Lin C, et al. Outcomes as a function of donor: recipient characteristics from a phase III study of belatacept vs cyclosporine in kidney transplantation (BENEFIT) [abstract no: 2857]. Transplantation 2010;90(Suppl):175.
172. Vincenti F, Grinyo J, Charpentier B, Pestana JM, Rostaing L, Vanrenterghem Y, et al. Primary outcomes from a randomized, phase III study of belatacept vs cyclosporine in kidney transplant recipients (BENEFIT study) [abstract no: SA-FC351]. Journal of the American Society of Nephrology 2009;20:82A.
173. Vincenti F, Grinyo J, Larsen C, Medina-Pestana J, Vanrenterghem Y, Dong Y, et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no: F564]. NDT Plus 2011;4(Suppl 2):4.s2.43.
174. Vincenti F, Grinyo J, Larsen C, Medina-Pestana J, Vanrenterghem Y, Duan T, et al. Benefit-risk profile of the belatacept LI regimen at 2 years in EBV(+) kidney transplant recipients [abstract no: 3370]. Transplantation 2010;90(Suppl):649. [EMBASE: 71532340]
175. Vincenti F, Grinyo JM, Charpentier B, Medina-Pestana JD, Rostaing L, Vanrenterghem Y, et al. Primary outcomes from a randomized, phase III study of belatacept vs cyclosporine in kidney transplant recipients (BENEFIT study) [abstract no: 4]. American Journal of Transplantation 2009;9(Suppl 2):191.
176. Vincenti F, Grinyo JM, Charpentier B, Medina-Pestana JD, Rostaing L, Vanrenterghem Y, et al. Primary outcomes from a randomized, phase III study of belatacept vs cyclosporine in kidney transplant recipients (BENEFIT study) [abstract no: O-331]. Transplant International 2009;22(Suppl 2):89.
177. Vincenti F, Larsen C, Alberu J, Garcia V, Rostaing L, Rice K, et al. Three year outcomes from BENEFIT: A phase III study of belatacept vs cyclosporine in kidney transplant recipients [abstract no: O-240]. Transplant International 2011;24(Suppl 2):68. [EMBASE: 70527316]
178. Vincenti F, Larsen C, Alberu J, Garcia V, Rostaing L, Rice K, et al. Three year outcomes from BENEFIT: A phase III study of belatacept vs cyclosporine in kidney transplant recipients [abstract no: O57]. Transplant International 2011;24(Suppl 3):21. [EMBASE: 70537323]
179. Vincenti F, Larsen C, Alberu J, Garcia VD, Rostaing L, Rice K, et al. Three-year outcomes from BENEFIT: a phase III study of belatacept vs cyclosporine in kidney transplant recipients [abstract no: SaO043]. NDT Plus 2011;4(Suppl 2):4.s2.18.
180. Vincenti F, Larsen C, Grinyo J, Charpentier B, Di Russo G, Garg P, et al. Renal benefit of belatacept vs cyclosporine in kidney transplant patients is not impacted by acute rejection (BENEFIT study) [abstract no: TH-PO1013]. Journal of the American Society of Nephrology 2009;20:342A.
181. Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. American Journal of Transplantation 2012;12(1):210-7. [MEDLINE: 21992533]
182. Vincenti F, Larsen CP, Alberu J, Garcia VD, Rostaing L, Rice K, et al. Three-year outcomes from BENEFIT: a phase III study of belatacept vs cyclosporine in kidney transplant recipients [abstract no: 227]. American Journal of Transplantation 2011;11(Suppl 2):99. [EMBASE: 70405262]
183. Vincenti F, Rostaing L, Durrbach A, Rice K, Pupim L, Grinyo J. Improving or maintaining renal function over 5 years with belatacept or cyclosporine (CsA): insights from the BENEFIT and BENEFIT-EXT long-term extension (LTE) studies [abstract no: SA-PO1012]. Journal of the American Society of Nephrology 2013;24(Abstracts):860A.
184. Vitalone MJ, Ganguly B, Li L, Hsieh SC, Latek R, Kulbokas E, et al. A comparison of kidney toxicity-related gene expression, chronic allograft injury and renal function in belatacept versus cyclosporine-treated patients [abstract no: CO53.02]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
185. Zhou Z, Shen J, Kaul S, Pfister M, Roy A. Belatacept population pharmacokinetics in renal transplant patients [abstract no: 1505]. American Journal of Transplantation 2010;10(Suppl 4):467.
186. Newell K, Mannon R, Mehta A, Tomlanovich S, Morrison Y, Ikle D, et al. Long-term calcineurin inhibitor (CNI) and corticosteroid (CS) avoidance using belatacept: the CTOT-10 experience [abstract no: 15]. American Journal of Transplantation 2013;13(Suppl 5):34. [EMBASE: 71056592]
187. Suessmuth Y, Stempora L, Johnson B, Cheeseman J, Morrison Y, Bridges N, et al. Comparison of baseline and day 28 post transplant renal allograft samples from the CTOT-10 belatacept study [abstract no: A630]. American Journal of Transplantation 2013;13(Suppl S5):225. [EMBASE: 71057206]
188. Ferguson R, Grinyo J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. American Journal of Transplantation 2011;11(1):66-76. [MEDLINE: 21114656]
189. Ferguson R, Vincenti F, Kaufman D, Woodle ES, Marder BA, Citterio F, et al. Immunosuppression with belatacept-based, CNI-avoiding and steroid-avoiding regimens vs a tacrolimus-based, steroid-avoiding regimen in kidney transplant patients: results of a 1-year, randomized study [abstract no: 1436]. Transplantation 2010;90(Suppl):156. [EMBASE: 71531403]
190. Ferguson R, Vincenti F, Kaufman DB, Woodle ES, Marder BA, Citterio F, et al. Immunosuppression with belatacept-based, CNI-avoiding and steroid-avoiding regimens vs a tacrolimus-based, steroid-avoiding regimen in kidney transplant patients: results of a 1-year, randomized study [abstract no: 372]. American Journal of Transplantation 2010;10(Suppl 4):150. [EMBASE: 70463733]
191. Grinyo J, Marder B, Harler M, Vincenti F, Citterio F, Nori U, et al. Outcomes at 4 years in a randomized trial evaluating belatacept-based regimens with simultaneous CNI and steroid-avoidance in kidney transplant [abstract no: 2162]. American Journal of Transplantation 2014;14(Suppl 3):116. [EMBASE: 71543897]
192. Grinyo J, Marder B, Harler M, Vincenti F, Citterio F, Nori U, et al. Outcomes at 4 years in a randomized trial evaluating belatacept-based regimens with simultaneous CNI and steroid-avoidance in kidney transplant [abstract]. Transplantation 2014;98(Suppl 1):116-7. [EMBASE: 71543897]
193. Grinyo J, Marks W, Vincenti F, Kaufman C, Marder B, Woodle S, et al. Immunosuppression with belatacept-based, CNI free, steroid avoiding regimens in kidney transplant recipients: 6 month, interim results [abstract no: O-336]. Transplant International 2009;22(Suppl 2):90-1.
194. Grinyo JM, Marks W, Vincenzi F, Kaufman DB, Marder BA, Woodle S, et al. Immunosuppression with belatacept-based, CNI-free, steroid-avoiding regimens in kidney transplant recipients: 6 month, interim results [abstract no: LB02]. American Journal of Transplantation 2009;9(Suppl 2):382. [EMBASE: 70010532]
195. Woodle E, Marder B, Harler M, Vincenti F, Citterio F, Nori U, et al. Renal function at 4 years in a phase 2 randomized trial evaluating belatacept-based regimens with simultaneous calcineurin inhibitor and corticosteroid avoidance in kidney transplant recipients [abstract no: 2157]. American Journal of Transplantation 2014;14(Suppl 3):114-5. [EMBASE: 71543892]
196. Woodle E, Marder B, Harler M, Vincenti F, Citterio F, Nori U, et al. Renal function at 4 years in a phase 2 randomized trial evaluating belatacept-based regimens with simultaneous calcineurin inhibitor and corticosteroid avoidance in kidney transplant recipients [abstract]. Transplantation 2014;98(Suppl 1):114-5. [EMBASE: 71543892]
197. Blancho G, Nashan B, Vincenti F, Charpentier B. Selective co-stimulation blockade with belatacept (LEA29Y) shows improved preservation of renal function at 12 months vs cyclosporine [abstract]. Transplant International 2005;18(Suppl 1):22.
198. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. American Journal of Transplantation 2008;8(10):2086-96. [MEDLINE: 18828769]
199. Charpentier B, Grannas G, Pearson T, Soulillou J, Vanrenterghem Y, Friend P, et al. Co-stimulation blockade with LEA29Y in renal transplant: improved renal function and cv/metabolic profile at 6 months compared with cyclosporine [abstract]. Transplantation 2004;78(2 Suppl):84.
200. Charpentier B, Larsen C, Grinyo J, Muehlbacher F, Blancho G, Grannas G, et al. Final results from the long term extension (LTE) of the belatacept phase 2 study in kidney transplantation [abstract no: 2164]. American Journal of Transplantation 2014;14(Suppl 3):117. [EMBASE: 71543899]
201. Charpentier B, Larsen C, Grinyo J, Muehlbacher F, Blancho G, Grannas G, et al. Final results from the long-term extension (LTE) of the belatacept phase 2 study in kidney transplantation [abstract]. Transplantation 2014;98(Suppl 1):117. [EMBASE: 71543899]
202. Chavez H, Beaudreuil S, Abbed K, Taoufic Y, Kriaa F, Charpentier B, et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transplant Immunology 2007;17(4):243-8. [MEDLINE: 17493526]
203. Friend P, Mühlbacher F, Charpentier B, Larsen C, Agarwal M, Vincenti F. Long-term safety of belatacept: 5 year results of a phase II study [abstract no: O46]. British Transplantation Society (BTS). 12th Annual Congress; 2009 Apr 21-24; Liverpool, UK. 2009.
204. Grannas G, Richter N, Klempnauer J, Lehner F. 10 years' experience with belatacept (Nulojix) [abstract no: PO27.012]. 24th International Congress of the Transplantation Society (TTS); 2012 Jul 15-19; Berlin, Germany. 2012.
205. Grimbert P, Audard V, Diet C, Matignon M, Plonquet A, Mansour H, et al. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. Nephrology Dialysis Transplantation 2011;26(3):1087-93. [MEDLINE: 20667993]
206. Grinyo J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010;90(12):1521-7. [MEDLINE: 21088650]
207. Grinyo J, Halloran P, Vanrenterghem Y, Pearson T, Nashan B, Sen K, et al. Belatacept (LEA29Y) as part of a CNI-free regimen in recipients of renal allografts with higher risk of poor long-term function and graft loss: comparison with cyclosporine A [abstract no: 946]. American Journal of Transplantation 2005;5(Suppl 11):397.
208. Hirose K, Posselt AM, Stock PG, Hirose R, Vincenti F. Treatment of kidney transplant patients with the novel co-stimulatory blocker LEA29y (BMS-224818) and antiil2 receptor antibody does not impede the development of regulatory t cells [abstract]. American Journal of Transplantation 2004;4(Suppl 8):442. [CENTRAL: CN-00509233]
209. Larsen C, Charpentier B, Wekerle T, Blancho G, Zhou W, Levy E, et al. Calcineurin inhibitor-free immunosuppression with belatacept (LEA29Y) in renal transplant: phase II 12-month results [abstract no: 535]. American Journal of Transplantation 2005;5(Suppl 11):293. [CENTRAL: CN-00764038]
210. Latek R, Fleener C, Lamian V, Kulbokas E, Davis PM, Suchard SJ, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009;87(6):926-33. [MEDLINE: 19300198]
211. Muehlbacher F, Charpentier B, Larsen C, Agarwal M, Vincenti F. Long-term safety of belatacept: 6 year results of a phase II study [abstract no: 621]. Transplantation 2008;86(2 Suppl):218.
212. Nashan B, Grinyo J, Vincenti F, Halloran P, Hagerty D, Zhou W, et al. Co-stimulation blockade with LEA29y in renal transplant: improved renal function and cv/metabolic profile at 6 months compared with cyclosporine [abstract]. American Journal of Transplantation 2004;4(Suppl 8):441. [CENTRAL: CN-00509129]
213. Shen J, Gelb JS, Townsend RM, Zhou Z, Pfister M, Harler MB, et al. Rationale for belatacept less intensive regimen in renal transplant recipients [abstract no: 1096]. American Journal of Transplantation 2011;11(Suppl 2):352. [EMBASE: 70406142]
214. Vincenti F. Costimulation blockade with belatacept in renal transplantation [abstract]. 8th International Conference on New Trends in Immunosuppression and Immunotherapy; 2008 Feb 14-17; Berlin, Germany. 2008.
215. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, et al. Five-year safety and efficacy of belatacept in renal transplantation. Journal of the American Society of Nephrology 2010;21(9):1587-96. [MEDLINE: 20634298]
216. Vincenti F, Durbach A, Larsen C, Muhlbacher F, Nashan B, LEA29Y SG. Study design and baseline characteristics of a multiple dose, randomized, controlled open-label study comparing a costimulation blocker based regimen of BMS-224818 (LEA29Y) vs. cyclosporine in renal transplant [abstract]. American Journal of Transplantation 2003;3(Suppl 5):473. [EMBASE: CN-00448208]
217. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, et al. Costimulation blockade with belatacept in renal transplantation. New England Journal of Medicine 2005;353(8):770-81. [MEDLINE: 16120857]
218. Vincenti F, Larsen C, Grinyo J, Muhlbacher F, Blancho G, Vanrenterghem Y, et al. A decade of treatment with belatacept in renal transplantation: final results from the long-term extension (LTE) of the phase 2 study [abstract no: SA-PO1013]. Journal of the American Society of Nephrology 2013;24(Abstracts):860A.
219. Vincenti F, Muehlbacher F, Nashan B, Larsen C, Atillasoy E, Natarajan K, et al. Co-stimulation blockade with LEA29y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-month efficacy and safety [abstract]. American Journal of Transplantation 2004;4(Suppl 8):442.
220. Wekerle T, Lang P, Larsen C, Muelbacher F. Selective co-stimulation blockade with belatacept (LEA29Y) results in decreased incidence of chronic allograft nephropathy in recipients of suboptimal renal allografts, compared with cyclosporine [abstract no: PO-274]. Transplant International 2005;18(Suppl 1):116.
221. Zhou Z, Shen J, Kaul S, Pfister M, Roy A. Belatacept population pharmacokinetics in renal transplant patients [abstract no: 1505]. American Journal of Transplantation 2010;10(Suppl 4):467.
222. Kamar N, Rial M, Alberu J, Steinberg S, Manfro R, Nainan G, et al. Three-years outcomes after switching to belatacept from calcineurin inhibitor in stable kidney transplant recipients [abstract]. Transplant International 2013;26(Suppl 3):22. [EMBASE: 71356163]
223. Kamar N, Rial M, Alberu J, Steinberg SM, Manfro R, Nainan G, et al. 3-year outcomes after switching to belatacept from a calcineurin inhibitor in stable kidney transplant recipients [abstract]. Transplant International 2013;26(Suppl 2):44. [EMBASE: 71359102]
224. Kirk A, Meas S, Xu H, Mehta A, Guasch A, Cheeseman J, et al. Kidney transplantation using alemtuzumab induction and belatacept/sirolimus maintenance therapy [abstract no: 56]. American Journal of Transplantation 2011;11(Suppl 2):45. [EMBASE: 70405091]
225. Kirk A, Mehta A, Guasch A, Mead S, Xu H, Cheeseman J, et al. Kidney transplantation using alemtuzumab induction and belatacept/sirolimus maintenance therapy [abstract no: 560]. American Journal of Transplantation 2012;12(Suppl 3):197. [EMBASE: 70746514]
226. Grinyo J, Alberu J, Contieri FL, Manfro RC, Mondragon G, Nainan G, et al. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transplant International 2012;25(10):1059-64. [MEDLINE: 22816557]
227. Grinyo J, Nainan G, Del Carmen RM, Steinberg S, Vincenti F, Dong Y, et al. Renal function at 2 years in kidney transplant recipients switched from ciclosporin or tacrolimus to belatacept: results from the long-term extension of a phase II study [abstract]. British Transplantation Society (BTS). 15th Annual Congress; 2012 Feb 22-24; Glasgow, UK. 2012.
228. Grinyo J, Nainan G, Del Carmen RM, Steinberg S, Vincenti F, Dong Y, et al. Renal function at 2 years in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: results from the long term extension of a phase II study [abstract no: O-245]. Transplant International 2011;24(Suppl 2):70.
229. Grinyo J, Nainan G, Del Carmen Rial M, Steinberg S, Vincenti F, Dong Y, et al. Renal function at 2 years in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: results from the long-term extension of a phase II study [abstract no: 567]. NDT Plus 2011;4(Suppl 2):4.s2.43.
230. Grinyo J, Nainan G, Rial M, Steinberg S, Vincenti F, Dong Y, et al. Renal function at 2 years in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: Results: from the long-term extension of a phase II study [abstract no: 226]. American Journal of Transplantation 2011;11(Suppl 2):99. [EMBASE: 70405261]
231. Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, Rial MC, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(2):430-9. [MEDLINE: 21051752]
232. Rostaing L, Nainan G, Del C Rial C, Steinberg S, Vincenti F, Shi R, et al. Switch from a CNI- to a belatacept-based immunosuppressive regimen in kidney transplant recipients is safe and results in better renal function: 12 month results from a phase II study [abstract no: 166]. American Journal of Transplantation 2010;10(Suppl 4):90. [EMBASE: 70463527]
233. Rostaing L, Nainan G, Del Carmen Rial M, Steinberg S, Vincenti F, Shi R, et al. Switch from a CNI- to a belatacept-based immunosuppressive regimen in kidney transplant recipients is safe and results in better renal function: 12 month results from a phase II study [abstract no: OSu022]. NDT Plus 2010;3(Suppl 3):iii285. [EMBASE: 70484172]
234. Rostaing L, Nainan G, Rial MC, Steinberg S, Vincenti F, Shi R, et al. Switch from a CNI to a belatacept-based immunosuppressive regimen in kidney transplant recipients is safe and results in better renal function: 12 month results from a phase II study [abstract no: 1446]. Transplantation 2010;90(Suppl):157. [EMBASE: 71531404]
235. Shen J, Lee S, Townsend R, Zhou Z, Roy A, Thomas D, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of belatacept in kidney transplant recipients (KTR) after conversion from CNI based regimens [abstract no: 939]. American Journal of Transplantation 2012;12(Suppl 3):301-2.
236. Walker RG, Rostaing L, Nainan G, Del C Rial M, Steinberg S, Vincenti F, et al. A switch to belatacept-based immunosuppressive regimen in kidney transplant recipients from calcineurin inhibitors (CNI) has a favourable safety profile and results in improved renal function: 12-month results from a phase II study [abstract no: 4]. Transplantation Society of Australia & New Zealand (TSANZ). 29th Annual Scientific Meeting 2011 June 29-Jul 1, Canberra, Australia. 2011:39.
237. EUCTR2006-003114-17. A randomized, open-label, multicenter, parallel-group study of belatacept-based corticosteroid-free regimens in renal transplant. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number (accessed 4 June 2014).
238. Moreso F. New-onset diabetes mellitus after renal transplantation. a multicentre, prospective, randomized, open study to evaluate belatacept-based versus tacrolimus-based immunosuppression. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number (accessed 4 June 2014).
239. Karlberg E. Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI). Open randomized 12 month study. www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001178-20 (accessed 4 June 2014).
240. Woodle S. Randomized, open label, multicenter study of belatacept-based early steroid withdrawal regimen with alemtuzumab or RATG induction compared to tacrolimus-based early steroid withdrawal regimen with RATG induction in renal transplantation [Belatacept early steroid withdrawal trial]. www.clinicaltrials.gov/ct2/show/NCT01729494 (accessed 26 May 2014).
241. Hesselink DA. Immune monitoring to characterize t-cell responses of kidney transplant patients during costimulation blockade by belatacept. www.trialregister.nl/trialreg/admin/rctview asp?TC=4242 (accessed 4 June 2014).
242. Clayton P, Hurst K, McDonald S, Chadban S. ANZDATA Registry Report 2012. Chapter 8: Transplantation. www.anzdata.org.au/anzdata/AnzdataReport/35thReport/2012c08_transplants_v1.5.pdf (accessed 11 November 2014):2-27.
243. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. JAMA 1996;276(8):637-9. [MEDLINE: 8773637]
244. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80(2 Suppl):S254-64. [MEDLINE: 16251858]
245. Dobbels F, Wong S, Min Y, Sam J, Kalsekar A. Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials. Transplantation 2014;98(9):960-8. [MEDLINE: 24831918]
246. Ekberg H, Bernasconi C, Tedesco-Silva H, Vitko S, Hugo C, Demirbas A, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. American Journal of Transplantation 2009;9(8):1876-85. [MEDLINE: 19563339]
247. Felchner SM, Glyda M, Cockfield S, Grinyo J, Legendre C, Russ G, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. American Journal of Transplantation 2011;11(8):1633-44. [MEDLINE: 21668635]
248. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. American Journal of Transplantation 2010;10(3):582-9. [MEDLINE: 20121740]
249. Godlee F, Groves T. The new BMJ policy on sharing data from drug and device trials. BMJ 2012;345:e37888.
250. Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. American Journal of Transplantation 2009;9(11):2532-41. [MEDLINE: 19843031]
251. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
252. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
253. Masson P, Duthie FA, Ruster LP, Kelly PJ, Merrifield A, Craig JC, et al. Consistency and completeness of reported outcomes in randomized trials of primary immunosuppression in kidney transplantation. American Journal of Transplantation 2013;13(11):2892-901. [MEDLINE: 24102933]
254. Meier-Kriesche HU, Schold JD, Srinvias TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. American Journal of Transplantation 2004;4(3):378-83. [MEDLINE: 14961990]
255. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 2009;151(4):264-9. [MEDLINE: 19622511]
256. Nankivell B, Borrows R, Fung C, O'Connell P, Allen R, Chapman J. The natural history of chronic allograft nephropathy. New England Journal of Medicine 2003;349(24):2326-33. [MEDLINE: 14668458]
257. Organ Procurement & Transplantation Network. optn.transplant.hrsa.gov/converge/data/ (accessed 11 November 2014).
258. Rao PS, Ojo A. The alphabet soup of kidney transplantation: SCD, DCD, ECD--fundamentals for the practicing nephrologist. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(11):1827-31. [MEDLINE: 19808229]
259. Sayegh M, Turka L. The role of T-cell costimulatory activation pathways in transplant rejection. New England Journal of Medicine 1998;338(25):1813-21. [MEDLINE: 9632449]
260. Scientific Registry of Transplant Recipients. 2010 Annual Report Data. srtr.transplant.hrsa.gov/annual_reports/2010/chapter_index.htm (accessed 11 November 2014).
261. Vanrenterghem Y, Claes K, Montagnino G, Fieuws S, Maes B, Villa M, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008;85(2):209-16. [MEDLINE: 18212625]
262. Vincenti F, Friman S, Scheurmann E, Rostaing L, Jenssen T, Campistol J, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. American Journal of Transplantation 2007;7(6):1506-14. [MEDLINE: 17359512]
263. Watson CJ, Firth J, Williams P, Bradley J, Pritchard N, Chaudhry A, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. American Journal of Transplantation 2005;5(10):2496-503. [MEDLINE: 16162200]
264. Webster AC, Taylor RR, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2]
265. Webster AC, Wong G, Craig JC, Chapman JR. Managing cancer risk and decision making after kidney transplantation. American Journal of Transplantation 2008;8(11):2185-91. [MEDLINE: 18782291]
266. White CA, Siegal D, Akbari A, Knoll GA. Use of kidney function end points in kidney transplant trials: a systematic review. American Journal of Kidney Diseases 2001;56(6):1140-57. [MEDLINE: 21036442]
267. Wong G, Howard K, Chapman JR, Chadban S, Cross N, Tong A, et al. Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PloS ONE 2012;7(1):e295291. [MEDLINE: 22279541]
268. Masson P, Henderson L, Chapman JR, Craig JC, Webster A. Belatacept for kidney transplant recipients. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD010699]